公开(公告)号：US20230374148A1

公开(公告)日：2023-11-23

申请号：US18248651

申请日：2021-10-14

Applicant: UCB BIOPHARMA SRL

Inventor： Stephen Edward RAPECKI ,  Ralph ADAMS ,  David Paul HUMPHREYS ,  Helen Margaret FINNEY ,  Rosemary Frances BITHELL

IPC: C07K16/28 ,  C07K16/18 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07K16/289 ,  C07K16/18 ,  A61P35/00 ,  A61P35/02 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/72 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2317/35

Abstract: The present invention provides binding molecule or molecules that are able to multimerise CD45 to induce cell death of a cell expressing CD45 without also inducing significant cytokine release. For example, the invention provides antibodies against CD45, wherein the antibodies comprise at least two different paratopes each specific for a different epitope of CD45. The antibodies may be used to cross-link CD45 on the surface of cells. The antibodies may be used in a variety of therapeutic ways including to deplete cells, for example prior to cell transplantation.

公开(公告)号：US20240067758A1

公开(公告)日：2024-02-29

申请号：US18255213

申请日：2021-12-06

Applicant: UCB BIOPHARMA SRL

Inventor： Joseph Michael David RASTRICK ,  John Paul SILVA ,  Daniel John LIGHTWOOD ,  Ralph ADAMS ,  Roger Thomas PALFRAMAN ,  Kerry Louise TYSON ,  Peter Charles ELLIOTT ,  Seema MAYANK ,  Andrea Julie CROSBY ,  Emily Mary Cairistine BARRY ,  Seppe Frans Roman LEYSEN ,  Zainab AHDASH

IPC: C07K16/46 ,  C12N15/63 ,  A61P17/00

CPC classification number: C07K16/468 ,  C12N15/63 ,  A61P17/00 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2317/565 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/14

Abstract: The present invention relates to antibodies binding to IL13 and IL22. The invention provides novel multi-specific antibodies that bind to both IL13 and IL22 and compositions comprising an antibody that binds to IL13 and an antibody that binds to IL22. The invention further relates to therapeutic uses of the combination of anti-IL13 and anti-IL22 antibodies and multi-specific antibodies that bind to both IL13 and IL22.

公开(公告)号：US20220220192A1

公开(公告)日：2022-07-14

申请号：US17585174

申请日：2022-01-26

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph ADAMS ,  Patrick DOWNEY ,  Terence Seward BAKER ,  Kerry Louise TYSON ,  Lorenzo DE LICHTERVELDE ,  Daniel John LIGHTWOOD ,  David James MCMILLAN

IPC: C07K16/18

Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

公开(公告)号：US20250011473A1

公开(公告)日：2025-01-09

申请号：US18755124

申请日：2024-06-26

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph ADAMS ,  Thomas Allen CESKA ,  Anna Marie DAVIES ,  Alistair James HENRY ,  Xiaofeng LIU ,  James Michael MCDONNELL ,  Brian John SUTTON ,  Marta Katarzyna WESTWOOD

IPC: C07K16/42 ,  A61P37/08 ,  C07K14/735 ,  C07K16/28

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

公开(公告)号：US20220235146A1

公开(公告)日：2022-07-28

申请号：US17541932

申请日：2021-12-03

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph ADAMS ,  Thomas Allen CESKA ,  Anna Marie DAVIES ,  Alistair James HENRY ,  Xiaofeng LIU ,  James Michael MCDONNELL ,  Brian John SUTTON ,  Marta Katarzyna WESTWOOD

IPC: C07K16/42 ,  C07K16/28 ,  C07K14/735 ,  A61P37/08

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

公开(公告)号：US20210166780A1

公开(公告)日：2021-06-03

申请号：US16972458

申请日：2019-06-05

Applicant: UCB Biopharma SRL

Inventor： Ralph ADAMS ,  James HEADS ,  Sebastian KELM ,  Alastair David Griffiths LAWSON

IPC: G16B15/20 ,  C07K16/00

Abstract: The present invention provides a method for generation of multi-domain proteins, more particular antibodies, with an improved native state colloidal stability.

公开(公告)号：US20210107971A1

公开(公告)日：2021-04-15

申请号：US16771993

申请日：2018-12-13

Applicant: UCB Biopharma SRL

Inventor： Ralph ADAMS ,  Patrick DOWNEY ,  Terence Seward BAKER ,  Kerry Louise TYSON ,  Lorenzo DE LICHTERVELDE ,  Daniel John LIGHTWOOD ,  David James MCMILLAN

IPC: C07K16/18

Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.